This article is provided by the customized enterprise intelligence intelligent service platform - [Intelligence Strong Enterprise].
Industry dynamics
Janssen's CAR-T multiple myeloma** was approved by the EMA
Label: car-t
Cilta-Cel is an innovative CAR-T** for BCMA and is used in patients with RMM. These patients have progressed on prior treatment with other** and are refractory to lenalidomide. This improves prognosis and is considered a new option for RRMM. Conditional marketing authorization has been granted and is expected to be converted to a standard authorization.
cilta cel is an innovative car-t therapy targeting bcma for the treatment of rrmm patients. these patients h**e previously received other treatments but their condition has progressed and are difficult to treat with lenalidomide. this therapy can improve prognosis and is considered a new treatment option for rrmm. we h**e obtained a conditional listing permit and are expected to switch to standard authorization.
China's fifth! CARsgen's BCMA CAR-T product, Zevogene autoleucel, was approved by the NMPA
Label: CAR-T T cells Legend Biologics.
On March 1, CARsgen announced that the National Medical Products Administration ("NMPA") has officially approved the New Drug Application ("NDA") for the treatment of patients with *** or refractory multiple myeloma** who have progressed after at least 3 lines**, and the drug is the fifth CAR-T product approved in China.
Biotech company Kenai Therapeutics has invested $82 million to launch Parkinson's Cells**
Label: Cell**.
San Diego-based biotechnology company Kenai Therapeutics has raised $82 million to develop cells for neurological diseases**. The latest drugs have shown positive effects in preclinical models of Parkinson's disease. The company plans to use the financing to advance the RNDP-001 drug into human testing and early clinical trials.
Aiming at trillions of frontier industries! Guangdong has accelerated the construction of five future industries such as cells
Label: Cell**.
On February 28, Guangdong Province issued the "Action Plan for Future Life and Health Industry Clusters", relying on Guangzhou, Shenzhen and other cities to develop future life and health industries such as gene technology and cell **. It is planned that by 2035, leading innovative enterprises will be cultivated and an industrial highland will be created. The five key projects include gene technology innovation, cell drug research and development, AI+ biomedical collaborative research, synthetic biology technology innovation, and brain science and brain-like research.
Cutting-edge technology
The next generation of CAR T cells** includes cancer inhibitors
Label: T cell
A team of researchers at the University of Pennsylvania has found that a variant of the p53 protein, Δ133p53, can enhance the effects of CAR T cells**. Expression of δ133p53 in CAR T cells can improve their metabolic stability and antitumor function, especially in the setting of high tumor burden. This discovery provides a new avenue for anti-cancer T cells.
the research team at the university of pennsylvania has discovered a variant of p53 protein δ 133p53 α it can enhance the effectiveness of car t cell therapy. expressed in car t cells δ 133p53 α it can improve its metabolic stability and anti-tumor function, especially under high tumor loads. this discovery provides a new therapeutic approach for anti-cancer t cells.
Recent research has improved the process to alleviate chromosome loss in T cells
Label: T cell viral vector.
A research team from three universities in the United States has found that CRISPR-Cas9 is prevalent in chromosome loss after editing T cells, affecting T cell function. This phenomenon persists in clinical trials. The team was able to improve the cell manufacturing process, reduce chromosome loss, and maintain gene editing efficiency.
Cell blockbuster: Chinese scholars have discovered for the first time that this hereditary blindness is actually caused by intestinal bacteria, and antibiotics can also be used**
Label: intestinal flora.
Scientists from Sun Yat-sen University and University College London published a study in the journal Cell and found that intestinal bacteria are present in retinal degeneration caused by CRB1 gene mutations, indicating that intestinal bacteria may be involved in this process, using antimicrobial drugs or normalizing CRB1 gene expression can prevent blindness, providing a new strategy for hereditary retinal degeneration.
adv sci |Yin Yuxin's team at Peking University discovered that tumor-associated monocytes reprogram CD8+ T cells into central memory T cells with potent anti-tumor effects
Label: T cells.
Yuxin Yin's team at Peking University found that tumor-associated monocytes (TAMOS) are highly correlated with the accumulation of CD8+ memory T cells in human cancers, and can reprogram CD8+ T cells into central memory T cells with powerful anti-tumor effects (T CM-like). Research provides new strategies to improve efficacy.
The content of this article is based on network information, which is organized by [Intelligence Strong Enterprise].